What happens to clinical skills when AI does the routine work?
-
By
-
Doug Brunk
-
September 1, 2026
-
7 min
By
Doug Brunk
September 1, 2026
Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.
September 1, 2026
Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
July 2, 2026
The assay is indicated to identify patients with advanced melanoma who have BRAF V600E or BRAF V600K variants and may benefit from FDA-approved targeted therapies.
August 10, 2026